DNA X, Inc. Reports Sale of Series B Shares; Says It Meets Nasdaq Equity Requirement

What Happened
DNA X, Inc. (SONM) filed a Form 8‑K/A (filed Aug 13, 2026) reporting that on August 7, 2026 it sold and issued the remaining 416,667 shares of Series B Preferred Stock under its Purchase Agreement for cash proceeds of $2.5 million (Item 3.02). In an Item 8.01 disclosure, the company provided a pro forma, unaudited presentation showing that, after the transaction and related adjustments, it believes its stockholders’ equity exceeds the $2.5 million minimum required for continued listing on The Nasdaq Capital Market under Listing Rule 5550(b)(1). DNA X is awaiting Nasdaq’s formal determination and will update the market when received.

Key Details

• Transaction date: August 7, 2026; filing date: August 13, 2026.
• Shares sold: 416,667 shares of Series B Preferred Stock for $2.5 million in cash.
• Pro forma ending stockholders’ equity (unaudited, in thousands): $5,840 (i.e., $5.84 million) as of Aug 7, 2026, per management’s estimates.
• Disclosures made under Item 3.02 (unregistered sale of equity securities) and Item 8.01 (other events); company is awaiting Nasdaq’s formal confirmation of compliance with the Equity Rule.

Why It Matters
Meeting Nasdaq’s $2.5 million stockholders’ equity threshold is a key listing requirement; the company reports that, on a pro forma basis after this sale and related adjustments, it is above that threshold. If Nasdaq formally confirms compliance, this would address a material listing standard and reduce immediate regulatory risk related to continued listing. Investors should note the pro forma figures are unaudited, based on management estimates, and the company has not yet received Nasdaq’s formal determination.